- |||||||||| Clinical, Journal: Charles Byrne, Last Victim of the Bodysnatchers: The Legal Case for Burial. (Pubmed Central) - Oct 1, 2021
The fifth, which underpins the rest, is that Byrne is not, and has never been property, and it is in fact intuitively and legally arguable that he, like other corpses, remains a person. The article finally outlines three options available to those wishing to ensure Byrne finally has the burial at sea that he sought to ensure in 1783.
- |||||||||| Avastin (bevacizumab) / Roche
Review, Journal: Radiation techniques in aggressive pituitary tumours and carcinomas. (Pubmed Central) - Sep 29, 2021
We will then discuss the anti-tumour and anti-secretory efficacy of radiation techniques in aggressive pituitary tumors, either as a single treatment or as part of a multimodal treatment. Finally we will discuss the technique-specific side-effects.
- |||||||||| Review, Journal: Acromegaly, inflammation and cardiovascular disease: a review. (Pubmed Central) - Sep 29, 2021
Previous studies suggest that insulin resistance, oxidative stress, and endothelial dysfunction are involved in the development of CVD in acromegaly. Not surprisingly, these processes are associated with systemic inflammation and respond to GH/IGF-1 normalizing treatment.
- |||||||||| Review, Journal: Multidisciplinary management of acromegaly: A consensus. (Pubmed Central) - Sep 29, 2021
Effects of treatment on patient outcomes were considered, along with strategies for optimizing and personalizing therapeutic approaches. Expert consensus recommendations emphasize how best to implement available treatment options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence.
- |||||||||| Somavert (pegvisomant) / Pfizer
Enrollment change: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Sep 28, 2021
P=N/A, N=76, Recruiting,
No abstract available N=51 --> 76
- |||||||||| Somavert (pegvisomant) / Pfizer
[VIRTUAL] Unusual Pediatric Cases of Acromegaly () - Sep 25, 2021 - Abstract #AAPNCE2021AAP_NCE_1667;
Pituitary adenoma presenting as acromegaly is rare in children and may present with unusual symptoms of other pituitary hormone dysfunction, like in our patients. Physicians need to consider evaluation for gigantism/acromegaly in children with pituitary tumors and abnormal growth findings.
- |||||||||| Complex Carotid Aneurysm Resection Requiring Mandibular Subluxation (Exhibit Hall) - Sep 25, 2021 - Abstract #ASA2021ASA_4016;
After an uneventful surgical procedure and mandibular reduction, the patient was extubated in the operating room. Postoperative course was complicated by obstruction of the oropharynx secondary to edema of the left hemitongue with tongue deviation and weakness, likely a sequelae of acute denervation injury due to unilateral hypoglossal nerve palsy.
- |||||||||| lidocaine topical / Generic mfg.
Difficult Airway Management In Transsphenoidal Surgery For Acromegaly (Exhibit Hall) - Sep 25, 2021 - Abstract #ASA2021ASA_3645;
Topicalized airway with nebulized 4% lidocaine and added lidocaine cream-soaked cotton tipped applicators to tonsillar pillars in preop...Intubated after 3 attempts with flexible fiberoptic endoscope. Surgery went well; extubated successfully in PACU after trial with tube-exchanger in-situ.
- |||||||||| Clinical, Journal: An early scientific report on acromegaly: solving an intriguing endocrinological (c)old case? (Pubmed Central) - Sep 24, 2021
In view of this rare association and, to date, endocrinological research, we hypothesize a further pathogenic mechanism by which acromegaly could have induced this massive dilatation. Taruffi's work represents an immensely valuable scientific/artistic heritage and is still cited in contemporary endocrinological literature, demonstrating its relevant contribution to the historical evolution of the disease through the nineteenth and twentieth centuries.
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide long acting release) / Novartis
Clinical, Journal: Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. (Pubmed Central) - Sep 22, 2021
Our data confirmed that glucose metabolism in patients treated with PAS-LAR is often worsened, and may be predicted by entity of baseline GH hypersecretion and by the dose of PAS-LAR. Moreover, our data, although limited by small numbers, may suggest that the combination treatment PAS-LAR + Peg-V can improve glucose homeostasis in selected patients.
- |||||||||| Journal: Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. (Pubmed Central) - Sep 22, 2021
Although markers of bone turnover elevated in acromegaly, they were not useful for the prediction of fractures. Serum sclerostin levels showed no discrepancy between the two groups and further studies are required for assessment of sclerostin role in this form of secondary osteoporosis.
- |||||||||| Clinical, Observational data, Journal, HEOR: Quality of Life in Patients with Acromegaly - A Romanian Single Center Cross-Sectional Study. (Pubmed Central) - Sep 21, 2021
The most frequent complications were cardiovascular complications (81.63%), articular complications (73.46%), dyslipidemia (65.30%) and digestive complications (63.26%). Despite complex treatment and hormonal control, the presence of complications reduces the quality of life in patients with acromegaly, even when compared with obese patients.
- |||||||||| Journal: Pituitary Surgery: Changing the Paradigm in Veterinary Medicine in the United States. (Pubmed Central) - Sep 19, 2021
It is well documented that dogs surgically treated when the pituitary mass is small have a lower mortality, a lower recurrence rate, and a longer survival than those with larger pituitary masses. Providing owners with the option of early pituitary imaging in addition to medical, surgical, and radiation treatment options should be the standard of care for animals diagnosed with pituitary-dependent hyperadrenocorticism or hypersomatotropism.
- |||||||||| Journal: Impact of experience on outcomes following endoscopic transsphenoidal surgery for acromegaly. (Pubmed Central) - Sep 19, 2021
We report, in this large single-surgeon review of endoscopically operated acromegaly cases, increased rates of surgical remission and reduced complications with increasing surgeon experience. The overall experience of the treating team in dealing with peri-operative and intra-operative factors also contribute to improved outcomes.
- |||||||||| Clinical, Journal: Pituitary Apoplexy Complicated by Cerebral Infarction: A Case Report. (Pubmed Central) - Sep 19, 2021
Neuroimaging revealed large hemorrhagic sellar mass and ischemic infarction in the left middle cerebral artery territory. Emergency transcranial tumor excision was done, which resulted in significant neurological recovery.
- |||||||||| Trial completion date, Trial primary completion date: Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly (clinicaltrials.gov) - Sep 16, 2021
P=N/A, N=20, Recruiting,
Emergency transcranial tumor excision was done, which resulted in significant neurological recovery. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| leuprorelin depot / Generic mfg.
Journal: Physical-chemical characterization of octreotide encapsulated in commercial glucose-star PLGA microspheres. (Pubmed Central) - Sep 16, 2021
Sandostatin LAR (SLAR) is an injectable long-acting release (LAR) microsphere formulation for octreotide based on a biodegradeable glucose star copolymer of d,l-lactic and glycolic acids (PLGA-glu), which is primarily used for the treatment of patients with acromegaly...Leuprolide is considered as a cationic peptide competitor for octreotide-PLGA interactions and its presence in the release medium resulted in more continuous octreotide release from SLAR, which was linearly correlated with the mass loss from the polymer (i.e., an indication of erosion-controlled release)...This salt is expected to catalyze octreotide acylation and extend peptide release beyond that is driven by erosion-control. The characterization studies of physicochemical properties of SLAR described here could be useful for development and regulatory evaluation of generic octreotide microspheres as well as new polymer formulations in which the polymer strongly interacts with encapsulated peptides.
- |||||||||| Clinical, Journal: Endocrine myopathies: clinical and histopathological features of the major forms. (Pubmed Central) - Sep 16, 2021
The diagnosis is usually easy if a muscle disorder occurs in an overt endocrinopathy; however, in few patients, myopathy could be the first manifestation of the underlying endocrinopathy. In this article we discuss pathophysiology, clinical features and management of muscle involvement related to the major endocrine diseases.
- |||||||||| Review, Journal: Pituitary Adenomas with Changing Phenotype: A Systematic Review. (Pubmed Central) - Sep 10, 2021
PA can change from functioning to (NF) non-functioning (vice versa) and even exchange their hormonal expression. Clinicians should be aware and a careful lifelong follow-up is mandatory to detect it.
- |||||||||| Somavert (pegvisomant) / Pfizer
Clinical, Retrospective data, Journal, Real-world evidence: More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. (Pubmed Central) - Sep 10, 2021
Clinicians should be aware and a careful lifelong follow-up is mandatory to detect it. This comprehensive review of the complete cohort in ACROSTUDY confirmed the overall favourable benefit-to-risk profile and high efficacy of PEGV as mono- and combination therapy in patients with an aggressive course/uncontrolled/active acromegaly requiring long-term medical therapy for control.
- |||||||||| paltusotine (CRN00808) / Crinetics
Journal: New and emerging pharmacological treatment options for acromegaly. (Pubmed Central) - Sep 8, 2021
Disease control is essential to reduce morbidity and mortality in acromegaly but is still not achieved in a significant proportion of patients or takes a long time to be achieved with currently available options and treatment algorithms. Therefore, the development of new drugs as well as the establishment of biomarkers of disease control to allow precision medicine will improve treatment and outcomes in acromegaly.
- |||||||||| Clinical, Journal: Somatostatin analogs in pregnant patients with neuroendocrine tumor. (Pubmed Central) - Sep 2, 2021
We report two cases of gastroenteropancreatic-NET patients receiving SSA lanreotide for the entire course of their pregnancy, with favorable outcomes for both mothers and babies. Our experience supports the possibility to continue safely SSA lanreotide during pregnancy in patients with NET.
- |||||||||| Clinical, Journal: Spontaneous remission of unidentified Cushing's disease revealed by hair cortisol analysis. (Pubmed Central) - Sep 1, 2021
However, we describe a patient with Cushing's disease presenting with pituitary apoplexy, who was biochemically in remission at presentation. The diagnosis could be confirmed in retrospect using hair cortisol analysis, thereby enabling clinicians to adequately anticipate remission of Cushing's disease.
- |||||||||| Clinical, Journal: Expression of plasma microRNA in patients with acromegaly (Pubmed Central) - Aug 27, 2021
we found four microRNAs, which could potentially be downregulated in plasma of patients with acromegaly. The result need to be validated using different measurement method with larger sample size.
- |||||||||| Journal: A novel peptide antagonist of the human growth hormone receptor. (Pubmed Central) - Aug 22, 2021
We observed a strong correlation between helical propensity and inhibitory effect, indicating that S1H-mediated antagonism of the hGHR is largely dependent on the ability for S1H to adopt an α-helix. Taken together, these results show that S1H not only acts as a novel peptide-based antagonist of the hGHR but can also be applied as a chemical tool to study the molecular nature of hGH-hGHR interactions.
- |||||||||| Trial completion date, Trial primary completion date, Surgery: Sleep Apnea in Acromegaly After Surgery (clinicaltrials.gov) - Aug 20, 2021
P=N/A, N=50, Recruiting,
Taken together, these results show that S1H not only acts as a novel peptide-based antagonist of the hGHR but can also be applied as a chemical tool to study the molecular nature of hGH-hGHR interactions. Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Dec 2021
|
